Amber Blease
Family · Moultrie, GANPI 1457758419
Payments from drug & device makers
Across 203 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Astellas Pharma US Inc$1K
- Sumitomo Pharma America, Inc.$703
- Urovant Sciences Inc$238
- Boston Scientific$150
- Myovant Sciences Inc.$123
- plus $413 from 11 others
What the payments were for
- Travel & lodging$1,06619%
- Food & beverage$3,97171%
- Education$59311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 83 | $2,999 |
| Astellas Pharma US Inc | 27 | $1,003 |
| Sumitomo Pharma America, Inc. | 50 | $703 |
| Urovant Sciences Inc | 18 | $238 |
| Boston Scientific | 2 | $150 |
| Myovant Sciences Inc. | 8 | $123 |
| AbbVie | 4 | $92 |
| Medtronic | 1 | $91 |
| BD | 1 | $38 |
| Pfizer | 2 | $36 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Millicent US Inc | 1 | $23 |
| Vertex | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| Solventum Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,630 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 444 | $258,397 |
| MyrbetriqMirabegron | 342 | $216,242 |
| LinzessLinaclotide | 51 | $33,020 |
| ElmironPentosan Polysulfate Sodium | 14 | $15,524 |
| Estradiol | 207 | $12,880 |
| Trimethoprim | 145 | $8,745 |
| Fosfomycin Tromethamine | 29 | $6,749 |
| Solifenacin Succinate | 228 | $6,028 |
| PremarinEstrogens, Conjugated | 11 | $4,919 |
| NitrofurantoinNitrofurantoin Macrocrystal | 155 | $3,837 |
| Oxybutynin Chloride ErOxybutynin Chloride | 251 | $3,529 |
| Methenamine Hippurate | 89 | $3,363 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 57 | $3,234 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 32 | $3,055 |
| Cefdinir | 119 | $2,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $703 | $258,397444 claims |
| Astellas Pharma US IncMyrbetriq | $1,003 | $216,242342 claims |
| AbbVieLinzess | $92 | $33,02051 claims |
| PfizerPremarin | $36 | $4,91911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Moultrie
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.